3-amino-1-benzyl-4,4-diethoxypiperidine | 167705-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-amino-1-benzyl-4,4-diethoxypiperidine
• 英文别名: 1-benzyl-4,4-diethoxy-piperidin-3-ylamine；1-Benzyl-4,4-diethoxypiperidin-3-amine
• CAS: 167705-70-6
• 化学式: C₁₆H₂₆N₂O₂
• 分子量: 278.395
• InChiKey: DIRRMKPRTNLWNU-UHFFFAOYSA-N

物化性质

• 沸点：
  360.1±42.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  47.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-1-benzyl-4,4-diethoxypiperidine 在 盐酸 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 36.0h， 生成 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine
  参考文献：
  名称：

  Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin

  摘要：

  By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization; of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.

  DOI：

  10.1021/acs.jmedchem.6b01634
• 作为产物：
  描述：

  N-苄基哌啶酮 在 吡啶 、 羟胺 、 potassium carbonate 、 sodium sulfate 作用下， 以 乙醇 为溶剂， 生成 3-amino-1-benzyl-4,4-diethoxypiperidine
  参考文献：
  名称：

  作为VEGFR-2激酶抑制剂的3-（4,5,6,7-四氢-3 H-咪唑并[4,5 - c ]吡啶-2-基）-1 H-喹啉-2-酮的设计与合成

  摘要：

  一系列3-（4,5,6,7-四氢-3 H-咪唑并[4,5- c ]吡啶-2-基）-1 H-喹啉-2-酮已被确定为一类新的VEGFR-2激酶抑制剂。合成了多种（4,5,6,7-四氢咪唑并[5,4- c ]吡啶-2-基）-乙酸乙酯，并评估了其对VEGFR-2的抑制活性。本文描述了该系列的制备以及化合物对VEGFR-2激酶活性的影响。

  DOI：

  10.1016/j.bmcl.2012.02.073

文献信息

• Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
  申请人：——

  公开号：US20030069230A1

  公开（公告）日：2003-04-10

  This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: 1 wherein Z is —C(O)— or —S(O) 2 —, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及一般为α-1A/B肾上腺素受体拮抗剂的化合物，其由式I表示： 1 其中Z为—C(O)—或—S(O) 2 —，X为碳或氮，Y为碳，X-Y一起被视为环A的两个相邻原子，所述环是一个由每个环中的一个到两个异原子（选自N、O或S）的五到六个原子的融合芳香环；其他取代基如规范中所定义；或其单体异构体、消旋或非消旋异构体混合物，或其药学上可接受的盐或溶剂化合物。该发明还涉及含有这种化合物的药物组合物，以及它们作为治疗剂的使用方法和制备方法。
• [EN] INDAZOLES<br/>[FR] INDAZOLES
  申请人：PFIZER LTD

  公开号：WO2013014567A1

  公开（公告）日：2013-01-31

  The present invention relates to compounds of formula (I) to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

  本发明涉及式(I)化合物及其药学上可接受的盐和该化合物及盐的药学上可接受的溶剂，其中取代基在此定义；含有这种化合物的组合物；以及这种化合物在治疗各种疾病，特别是哮喘和慢性阻塞性肺疾病中的用途。
• Imidazo-benzothiazoles
  申请人：——

  公开号：US20040229862A1

  公开（公告）日：2004-11-18

  The invention relates to 2-imidazo-benzothiazoles of general formula 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R′, R″, X, R′″ and n are defined herein, or a pharmaceutically acceptable salt thereof. It has been found that the compound of formula I are adenosine receptor ligands with good affinity to the A 1 and A 3 receptors. These compounds have useful pharmaceutical activities.

  这项发明涉及一般公式1中的2-咪唑-苯并噻唑，其中R1、R2、R3、R4、R5、R6、R7、R′、R″、X、R′″和n在此处有定义，或其药用可接受的盐。已发现公式I的化合物是与A1和A3受体具有良好亲和力的腺苷受体配体。这些化合物具有有用的药用活性。
• Synthetic applications of 2-aryl-4-piperidones. X Synthesis of 3-aminopiperidines, potential substance P antagonists
  作者：Anna Diez、Aline Voldoire、Isabel López、Mario Rubiralta、Víctor Segarra、Lluís Pagès、JoséM Palacios

  DOI：10.1016/0040-4020(95)98710-y

  日期：1995.4

  A general method is described for the synthesis of 3-aminopiperidines from 4-piperidones based on a KOEt treatment of the tosylate of the corresponding oximes (Neber rearrangement). The procedure is applied to the synthesis of N-benzyl-3-amino-4,4-diethoxypiperidine (13), (R)-N-(2-hydroxy-1-phenyl)ethyl analogues 18, and 2-phenyl derivatives 27–28. The methoxybenzylation of the primary amino group

  描述了基于对相应的肟的甲苯磺酸酯的甲苯磺酰脲（KOBER）处理从4-哌啶酮合成3-氨基哌啶的一般方法（Neber重排）。该方法适用于合成N-苄基-3-氨基-4,4-二乙氧基哌啶（13），（R）-N-（2-羟基-1-苯基）乙基类似物18和2-苯基衍生物27 –28。这些氨基哌啶的伯氨基的甲氧基苄基化作用导致一系列潜在的P物质拮抗剂。
• Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors
  作者：Sun-Young Han、Jie Won Choi、Jeon Yang、Chong Hack Chae、Jongkook Lee、Heejung Jung、Kwangho Lee、Jae Du Ha、Hyoung Rae Kim、Sung Yun Cho

  DOI：10.1016/j.bmcl.2012.02.073

  日期：2012.4

  A series of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones have been identified as a new class of VEGFR-2 kinase inhibitors. A variety of (4,5,6,7-tetrahydro-imidazo[5,4-c]pyridin-2-yl)-acetic acid ethyl esters were synthesized, and their VEGFR-2 inhibitory activity was evaluated. Described herein are the preparation of the series and the effects of the compounds on VEGFR-2

  一系列3-（4,5,6,7-四氢-3 H-咪唑并[4,5- c ]吡啶-2-基）-1 H-喹啉-2-酮已被确定为一类新的VEGFR-2激酶抑制剂。合成了多种（4,5,6,7-四氢咪唑并[5,4- c ]吡啶-2-基）-乙酸乙酯，并评估了其对VEGFR-2的抑制活性。本文描述了该系列的制备以及化合物对VEGFR-2激酶活性的影响。